若生智能
Drug Database
LO

Loxosceles Immune F(Ab)2 (Reclusmyn)

✓ Approved

Instituto Bioclon · 多克隆抗体 · 多克隆抗体

什么是 Loxosceles Immune F(Ab)2？

Loxosceles Immune F(Ab)2 是一种多克隆抗体，由Instituto Bioclon研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intravenous (IV)。

药物档案

商品名Reclusmyn
公司Instituto Bioclon
药物类别多克隆抗体, 抗体
给药途径Injectable (Others), Intravenous (IV)
状态Approved
来源： ClinicalTrials.gov, Instituto Bioclon

治疗适应症

Loxosceles Immune F(Ab)2 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Injury, poisoning and procedural complicationsVenom poisoning✓ Approved

相关研究文献

PubMedFrontiers in immunology2026-08-04

Comparison of the protective effect of human respiratory syncytial virus Pre-F protein combined with different adjuvants in BALB/c mice.

Chu Mengxuan M, Du Liang L, Hu Hongqiao H, Cao Lei L et al.

Human respiratory syncytial virus (HRSV) has a high disease burden in infants and elderly individuals. In this study, the adjuvants AlOH, AlOH+CpG and BFA03 were used to compare the protective effect of HRSV prefusion protein (Pre-F) in BALB/c mice. We divided BALB/c mice into three experimental groups (Pre-F+AlOH+CpG, Pre-F+AlOH, and Pre-F+BFA03) and three adjuvant control groups (AlOH+CpG, AlOH, and BFA03). After two intramuscular immunizations, we measured serum neutralizing antibody titers and quantified the numbers of IFN-γ- and IL-4-secreting lymphocytes. After viral challenge, we monitored body weight changes, determined lung viral loads (Ct values), and scored lung pathological damage. The mice in the experimental groups exhibited high titres of neutralizing antibodies and increased numbers of IFN-γ- and IL-4-secreting lymphocytes. The mice began to regain weight on the third day after challenge, but the mice in the adjuvant groups continued to lose weight. The mice immunized with Pre-F+BFA03 elicited the highest neutralizing antibody titre (1716), the lowest viral load in the lung, and milder pathological damage. The mice immunized with Pre-F+AlOH had the most severe lung pathological injury (score: 2.83) and the highest viral load in the lung (Ct value: 32.2). Compared with the BFA03 adjuvant, the AlOH adjuvant induced a Th2-biased humoral immune response in mice. The Pre-F+AlOH+CpG group had the least pathological damage in the lung (score 2.16), and the ability to induce neutralizing antibodies and cellular immune responses was comparable with that of the BFA03 adjuvant. These findings indicate that Pre-F protein combined with AlOH+CpG or BFA03 adjuvant provided similar protection in mice and both were superior to the AlOH adjuvant, providing a reference for adjuvant selection and formulation strategies in HRSV Pre-F protein vaccine development.

PMID 42548738
阅读全文 →
PubMedCurrent research in parasitology & vector-borne diseases2026-08-04

A newly developed rapid K39-based LeishmaCHECK Ab ELISA for high-throughput serological screening of canine leishmaniasis.

Ferrero Irene I, Poletti Paolo P, Giachino Enrica E, Filipe Joel J et al.

Canine leishmaniasis (CanL) is a zoonotic vector-borne disease caused by Leishmania infantum, with dogs acting as the main reservoir for human infection. Reliable serological assessment is essential for disease surveillance and control. This study describes the development and validation of LeishmaCHECK Ab ELISA, a new rapid qualitative and semi-quantitative assay for the detection of anti-L. infantum antibodies in canine serum. Cut-off values were established using multiple statistical approaches, including Youden's index and receiver operating characteristic (ROC) curve analysis. The assay was evaluated on 552 canine samples (313 positives, 206 negatives, 33 borderline), using IFAT as the reference serological method. LeishmaCHECK Ab ELISA showed excellent agreement with IFAT (Cohen's kappa of 0.93), achieving a relative sensitivity of 95.2% and a relative specificity of up to 99.5%. Comparative analyses also demonstrated superior diagnostic performance compared with other commercially available ELISA tests. These findings indicate that LeishmaCHECK Ab ELISA represents a reliable alternative tool for the serological screening of canine leishmaniasis.

PMID 42548988
阅读全文 →
PubMedEuropean archives of psychiatry and clinical neuroscience2026-08-04

Effects of an internet-based combined exercise and cognitive-behavioral therapy intervention on endocannabinoid system biomarkers and physical fitness in adults with mild-to-moderate depression: a SONRIE randomized controlled trial.

Ruiz-Muñoz Manuel M, Jiménez-Pavón David D, Garrido-Palomino Inmaculada I, Escudier-Vázquez Juan Manuel JM et al.

This SONRIE randomized controlled trial (NCT05849792) examined the effects of a 12-week combined physical exercise and internet-based cognitive-behavioral therapy (iCBT) intervention on endocannabinoid system (ES) biomarkers and physical fitness in adults with mild-to-moderate depression. Eighty adults were randomly assigned 1:1 to an intervention (IG) or control (CG) group. Outcomes included nine ES biomarkers (2-arachidonoylglycerol, 2-AG; anandamide, AEA; seven analogues) and physical fitness, including cardiorespiratory fitness (CRF; 6-minute walking test) and muscular strength. Measurements were taken at baseline, post-intervention and 8-week follow-up. Primary analysis performed 2 × 3 repeated-measures ANOVA on completers; mixed-effects intention-to-treat model as sensitivity analysis. No significant time × group interaction was detected for any ES biomarker, including 2-AG (F(2,88) = 0.17, p = 0.844) and AEA (F(2,88) = 1.20, p = 0.306); both groups showed comparable within-group decreases in 2-AG, 2-LG and 2-OG. The intervention significantly improved CRF [between-group difference + 81.6 m at 12 weeks (F(2,78) = 7.88, p = 0.001)], exceeding the established minimal clinically important difference. None of the exploratory muscular fitness outcomes reached statistical significance; the arm curl test showed a borderline non-significant interaction (F(2,78) = 2.83, p = 0.065). A 12-week internet-based combined exercise and iCBT intervention significantly improved CRF in adults with mild-to-moderate depression. We did not find evidence of an intervention-specific effect on plasma ES biomarkers. These findings support the inclusion of internet-delivered exercise and psychological interventions in comprehensive treatment strategies for depression. ClinicalTrials.gov NCT05849792 (registered 6 May 2023).

PMID 42550192
阅读全文 →
PubMedInvestigative ophthalmology & visual science2026-08-04

Z-Nucleic Acids: A Regulator of Macrophage PANoptosis and Fungal Biofilm in Fungal Keratitis.

Gao Ning N, Ma Yulin Y, Zhang Mengyu M, Cui Mengchen M et al.

This study aimed to investigate the role of Z‑nucleic acids (Z‑NAs) in the pathogenesis of fungal keratitis (FK), focusing on its regulatory effects on fungal immune escape, inflammation, and biofilm activity. A mouse model of FK was established by the combination of stromal scrapes and corneal contact lens with Fusarium solani. Disease severity was assessed using clinical scoring and histopathological examination. In vitro, bone marrow-derived macrophages (BMDMs) were infected with F. solani, and the efficiency of fungal phagocytosis and escape by BMDMs was determined through fungal counting. The expression of Z‑DNA binding protein 1 (ZBP1)-PANoptosis markers in corneal tissues and BMDMs was detected by western blot, and the localization of Z-NAs in these samples was examined by immunofluorescence staining. Additionally, Z‑NA expression within in vitro fungal biofilms was detected by immunofluorescence, and its roles in modulating biofilm activity, antifungal drug resistance, and chemotactic ability were further characterized. ZBP1-PANoptosis was significantly activated in FK corneal tissues and positively correlated with clinical severity in FK. F. solani infection triggered Z‑NA transformation and ZBP1-PANoptosis activation in BMDMs, which in turn promoted fungal immune escape and exacerbated inflammation. Z‑NAs accumulated as extracellular DNA in fungal biofilms and were shown to regulate biofilm activity, drug resistance, and chemotaxis. Z‑NAs play a dual pathogenic role in FK by inducing ZBP1-PANoptosis in macrophages and enhancing biofilm function, thereby promoting the progression of FK.

PMID 42549841
阅读全文 →
PubMedRadiology2026-08-04

Comparison of Second-line Hepatic Arterial Infusion Chemotherapy and Tyrosine Kinase Inhibitors in Advanced Hepatocellular Carcinoma.

Yoo Jae-Sung JS, Tak Kwon Yong KY, Cho Hee Sun HS, Han Ji Won JW et al.

Background With the advent of immune checkpoint inhibitor-based combination therapy, treatment sequencing for advanced hepatocellular carcinoma (HCC) has become increasingly complex. The Barcelona Clinic Liver Cancer (BCLC) 2026 recommendations emphasize individualized decision-making. Purpose To compare clinical outcomes of hepatic arterial infusion chemotherapy (HAIC) and tyrosine kinase inhibitors (TKIs) in patients with advanced HCC after atezolizumab-bevacizumab (AB) failure, within the BCLC 2026 treatment paradigm. Materials and Methods This multicenter retrospective study included patients who received AB and subsequently received either HAIC or a TKI between March 2022 and August 2025. HAIC used a cisplatin-fluorouracil regimen, and TKIs were given at standard doses. Tumor response and progression-free survival (PFS) were assessed using contrast-enhanced multiphase CT or liver MRI according to routine clinical practice. Imaging was reviewed by radiologists blinded to treatment allocation. Inverse probability of treatment weighting (IPTW) was applied for age, sex, Eastern Cooperative Oncology Group performance status, Child-Pugh class, portal vein tumor thrombosis, and tumor burden based on the up-to-seven criteria. Results This study included 90 patients (mean age, 62 years ± 10.9 [SD]; 73 men; HAIC group, n = 51; TKI group, n = 39). Baseline tumor burden was higher in the HAIC group than in the TKI group (percentage of patients with tumors beyond the up-to-seven criteria: 88% [45 of 51] vs 64% [25 of 39]; P = .01). In unweighted analyses, median overall survival (OS) was similar between the HAIC and TKI groups (10.4 vs 6.4 months; P = .62), whereas PFS favored HAIC over TKIs (median, 5.3 vs 3.6 months; P = .008). Objective response rate and disease control rate were higher with HAIC than with TKIs (objective response rate: 35% [18 of 51] vs 5% [two of 39], P = .002; disease control rate: 67% [34 of 51] vs 26% [10 of 39], P < .001). After IPTW, HAIC remained associated with longer PFS than TKIs (median, 7.1 vs 3.4 months; P < .001), and OS remained similar between groups (median, 10.5 vs 6.3 months; P = .32). Conclusion In patients with advanced HCC, after AB failure, second-line HAIC yielded higher response rates and longer PFS than TKIs. © RSNA, 2026 Supplemental material is available for this article. See also the editorial by Deyirmendjian and Tang in this issue.

PMID 42550027
阅读全文 →
PubMedSmall (Weinheim an der Bergstrasse, Germany)2026-08-04

Regulating MXene Functionalization and Oxidation for High-Rate, High Mass-Loading Supercapacitors.

Zheng Wei W, Guo Miaoxi M, Zhang Mutian M, Liu Xiang X et al.

Unlocking the commercial potential of MXene electrodes in high-energy supercapacitors requires overcoming a fundamental limitation: severe performance decay at increased electrode thickness and mass loading. This work resolves the intrinsic trade-off between surface functionalization and oxidation in MXene chemistry regulation by constructing a controlled redox environment. A urea-assisted hydrothermal process effectively removes inert -F terminations while inducing the formation of a 3D MXene hydrogel enriched with -N active sites. Concurrently, L-ascorbic acid is introduced as an antioxidant to suppress structural oxidation and enhance stability. As a result, the optimized MXene exhibits superior rate capability and long-term cycling stability under high mass loadings. Specifically, at 10.97 mg cm-2, a high specific capacitance of 597 F g-1 is achieved at 1 A g-1, with 69.66% retention at 50 A g-1, significantly outperforming that of pristine MXene (23.44%) and N-doped MXene (59.03%). Even at an ultrahigh loading of 108.64 mg cm-2, 44.50% of the capacitance is retained (from 564 F g-1 to 251 F g-1) over the current density range of 1 to 20 A g-1. This work establishes an effective strategy for designing high-performance MXene-based electrodes via reaction pathway regulation, enabling practical operation at commercially relevant mass loadings.

PMID 42549626
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多Loxosceles Immune F(Ab)2